查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1871569

肿瘤和血液学分子检测市场报告：趋势、预测和竞争分析（至2031年）

Onco-Hematology Molecular Testing Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球肿瘤和血液分子检测市场前景广阔，主要得益于国家级参考/专科检查室、大学附属检查室和社区医院市场的发展机会。预计2025年至2031年，全球肿瘤和血液分子检测市场将以6.5%的复合年增长率成长。推动该市场成长的关键因素包括：对个人化医疗和标靶治疗日益增长的需求，以及分子检测技术的进步，这些进步提高了诊断的准确性。

  • 根据 Lucintel 的预测，按类型划分，国家参考检查室预计在预测期内仍将是最大的细分市场。
  • 根据应用情况来看，国家参考检查室/专业检查室预计将呈现更高的成长率。
  • 从区域来看，预计亚太地区在预测期内将达到最高的成长率。

肿瘤和血液分子检测市场的最新趋势

全球肿瘤和血液学分子检测市场受到多种新兴趋势的驱动，这些趋势正在塑造未来诊断和治疗策略。这些趋势凸显了技术进步、精准医疗和个人化医疗的发展。

  • 次世代定序（NGS）技术的进步：NGS技术彻底改变了分子检测，能够检测骨髓恶性肿瘤中多种基因突变。这项技术可以进行全面的基因分析，从而深入了解预后、疾病进展和治疗反应，最终为血液系统癌症患者提供更个人化的治疗。
  • 液态生物检体简介：液态生物检体作为一种非侵入性替代传统切片检查的方法，正日益普及。它可以透过血液样本检测基因突变和改变，从而更容易监测疾病进展和治疗反应，尤其是在白血病等血液癌症的治疗中，传统切片检查方法在这些疾病的治疗中更具挑战性。
  • 标靶治疗的整合：分子检测在识别标靶治疗的生物标记和提高治疗效果方面发挥关键作用。针对特定基因突变的标靶治疗越来越受欢迎，因为它们可以最大限度地减少副作用并改善治疗效果，尤其是在淋巴瘤和骨髓瘤等血液癌症患者中。
  • 人工智慧和机器学习在诊断中的应用：人工智慧 (AI) 和机器学习在分子检测中的应用正在提高诊断准确性。人工智慧正被用于快速分析基因数据，从而实现骨髓恶性肿瘤的早期检测和个人化治疗方案的製定，最终有助于改善临床决策。
  • 扩大检测覆盖范围：新兴市场医疗服务可近性的改善正在推动肿瘤和分子血液检测的普及。各国政府、医疗机构和诊断公司正携手合作，致力于降低这些先进检测技术的成本，提高其可近性，从而在资源匮乏地区实现早期诊断和改善治疗效果。

全球肿瘤和血液学分子检测市场的新兴趋势正在改变诊断、治疗方法和患者照护。从次世代定序和液态生物检体的兴起，到人工智慧和标靶治疗的整合，这些趋势正使个人化、非侵入性诊断更加普及和精准。这些技术的日益普及有望改善患者预后，并推动肿瘤血液学检测领域的重大进步。

肿瘤和血液分子检测市场的最新趋势

全球肿瘤和血液学分子检测市场的最新发展反映了提高诊断准确性和改善患者预后的持续努力。这些发展是由技术创新和对个人化医疗日益增长的需求所驱动的。

  • 美国食品药物管理局（FDA）核准多种分子诊断工具：在美国，多种用于血液癌症的分子诊断工具已获得FDA核准，从而能够更早发现癌症并改善治疗监测。这些核准进一步凸显了分子检测在血液癌症管理中的重要性，并为在临床实践中采用更先进的技术铺平了道路。
  • 液态生物检体在血液癌症检测中的应用：液态生物检体的广泛应用正在改变血液癌症的诊断和后续观察。液态生物检体使临床医生能够利用血液样本追踪基因突变和疾病进展，为白血病和淋巴瘤患者提供了一种微创便捷的检测选择。
  • 次世代定序(NGS) 平台的技术进步：更精准、更经济的 NGS 平台的开发，正使分子检测在全球范围内更加普及。 NGS 能够更有效地识别罕见突变和基因改变，提供全面的基因组数据，从而实现精准医疗，改善血液肿瘤患者的治疗效果。
  • 携手提升检测可及性：医疗服务提供者、诊断公司和政府机构之间加强合作，正在改善已开发国家和开发中国家分子检测的可及性。这些伙伴关係旨在降低分子检测技术的成本，使其惠及更多患者。
  • 人工智慧在分子检测数据分析中的应用：人工智慧正被整合到分子检测平台中，以更有效率地分析复杂的基因数据。透过提高数据解读的速度和准确性，人工智慧正在帮助临床医生就治疗方案和疾病监测做出更明智的决策。

这些关键进展正对全球肿瘤和血液学分子检测市场产生深远影响。从核准和液态生物检体的普及，到次世代定序（NGS）技术的进步和人工智慧的整合，这些创新正在提升诊断能力，实现更个人化的治疗，并拓展分子检测的应用范围。这些进展共同预示着肿瘤和血液学医疗保健将迎来一个更精准、便利的未来。

目录

第一章执行摘要

第二章 市场概览

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 产业驱动因素与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

第四章 全球肿瘤和血液分子检测市场（按类型划分）

  • 概述
  • 吸引力分析：按类型
  • qPCR：趋势与预测（2019-2031）
  • dPCR：趋势与预测（2019-2031）
  • 次世代定序：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031 年）

5. 全球肿瘤和血液分子检测市场（按应用划分）

  • 概述
  • 吸引力分析：依目的
  • 国家检查室/专业检查室：趋势与预测（2019-2031）
  • 大学医院：趋势与预测（2019-2031 年）
  • 社区医院：趋势与预测（2019-2031 年）

第六章 区域分析

  • 概述
  • 全球肿瘤和血液分子检测市场（按地区划分）

7. 北美肿瘤与血液分子检测市场

  • 概述
  • 北美肿瘤和血液分子检测市场（按类型划分）
  • 北美肿瘤和血液分子检测市场按应用领域划分
  • 美国肿瘤与血液分子检测市场
  • 墨西哥肿瘤和血液分子检测市场
  • 加拿大肿瘤和血液分子检测市场

8. 欧洲肿瘤和血液分子检测市场

  • 概述
  • 欧洲肿瘤和血液学分子检测市场（按类型划分）
  • 欧洲肿瘤和血液分子检测市场按应用领域划分
  • 德国肿瘤与血液分子检测市场
  • 法国肿瘤与血液学分子检测市场
  • 西班牙肿瘤和血液学分子检测市场
  • 义大利肿瘤和血液分子检测市场
  • 英国肿瘤与血液分子检测市场

9. 亚太地区肿瘤与血液学分子检测市场

  • 概述
  • 亚太地区肿瘤和血液学分子检测市场（按类型划分）
  • 亚太地区肿瘤和血液分子检测市场（按应用划分）
  • 日本肿瘤与血液分子检测市场
  • 印度肿瘤和血液分子检测市场
  • 中国肿瘤与血液分子检测市场
  • 韩国肿瘤和血液分子检测市场
  • 印尼肿瘤与血液分子检测市场

10. 世界其他地区（ROW）肿瘤和血液学分子检测市场

  • 概述
  • ROW肿瘤和血液分子检测市场按类型划分
  • ROW肿瘤和血液分子检测市场按应用领域划分
  • 中东肿瘤与血液学分子检测市场
  • 南美洲肿瘤和血液分子检测市场
  • 非洲肿瘤与血液学分子检测市场

第十一章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 透过申请获得发展机会
  • 全球肿瘤和血液学分子检测市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 企业合併、协议、合作关係和合资企业

第十三章：价值链中主要企业的概况

  • 竞争分析
  • Asuragen
  • Bio-Rad Laboratories
  • Illumina
  • QIAGEN
  • Cepheid

第十四章附录

  • 图表清单
  • 表格列表
  • 分析方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于 Lucintel
  • 询问

The future of the global onco-hematology molecular testing market looks promising with opportunities in the national reference lab / specialty lab, university hospital, and community hospital markets. The global onco-hematology molecular testing market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are the growing demand for personalized medicine and targeted therapies and the advancements in molecular testing technologies enabling better diagnostic accuracy.

  • Lucintel forecasts that, within the type category, national reference lab will remain the largest segment over the forecast period.
  • Within the application category, national reference lab/ specialty labs is expected to witness the higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Onco-Hematology Molecular Testing Market

The global market for onco-hematology molecular testing is driven by several emerging trends that are shaping the future of diagnostics and treatment strategies. These trends highlight advancements in technology, precision medicine, and personalized care.

  • Next-Generation Sequencing (NGS) Advancements: NGS technology is revolutionizing molecular testing, enabling the detection of a wide range of genetic mutations in hematologic malignancies. This technology allows for comprehensive genetic profiling, offering insights into prognosis, disease progression, and treatment response, leading to more personalized care for patients with blood cancers.
  • Liquid Biopsy Adoption: Liquid biopsy is gaining traction as a non-invasive alternative to traditional biopsy methods. It enables the detection of genetic mutations and alterations through blood samples, making it easier to monitor disease progression and treatment efficacy. Liquid biopsy is particularly valuable for managing hematologic cancers like leukemia, where traditional biopsy methods may be challenging.
  • Targeted Therapy Integration: Molecular testing plays a critical role in identifying biomarkers for targeted therapies, enhancing treatment efficacy. Targeted treatments tailored to specific genetic mutations are gaining popularity, as they help minimize side effects and improve patient outcomes, particularly for patients with hematologic cancers like lymphoma and myeloma.
  • AI and Machine Learning in Diagnostics: The integration of artificial intelligence (AI) and machine learning in molecular testing is enhancing diagnostic accuracy. AI is being used to analyze genetic data quickly, enabling earlier detection of hematologic malignancies and the identification of personalized treatment plans, ultimately improving clinical decision-making.
  • Expansion of Testing Access: Increasing healthcare access in emerging markets is leading to the wider adoption of onco-hematology molecular testing. Governments, healthcare providers, and diagnostic companies are working together to make these advanced testing technologies more affordable and accessible, ultimately improving early diagnosis and treatment outcomes in underserved regions.

Emerging trends in the global onco-hematology molecular testing market are reshaping diagnostics, treatment approaches, and patient care. From the rise of next-generation sequencing and liquid biopsies to the integration of AI and targeted therapies, these trends are making personalized, non-invasive diagnostics more accessible and precise. The growing adoption of these technologies is set to improve patient outcomes and drive significant advancements in onco-hematology testing.

Recent Developments in the Onco-Hematology Molecular Testing Market

Recent advancements in the global onco-hematology molecular testing market reflect ongoing efforts to improve diagnostic accuracy and patient outcomes. These developments are driven by technological innovations and increased demand for personalized medicine.

  • FDA Approvals for Molecular Diagnostic Tools: In the U.S., several molecular diagnostic tools for hematologic cancers have received FDA approval, enabling better early detection and treatment monitoring. These approvals validate the importance of molecular testing in managing blood cancers, and they open the door for more advanced technologies in clinical practice.
  • Adoption of Liquid Biopsy in Hematologic Cancer Testing: The widespread use of liquid biopsy is transforming how hematologic cancers are diagnosed and monitored. Liquid biopsy allows clinicians to track mutations and disease progression using blood samples, which is particularly useful for patients with leukemia or lymphoma, offering a less invasive and more convenient testing method.
  • Technological Advancements in NGS Platforms: The development of more accurate and cost-effective NGS platforms is making molecular testing more accessible globally. With enhanced capabilities to identify rare mutations and genetic changes, NGS is enabling precision medicine and improving treatment outcomes for patients with hematologic cancers by providing comprehensive genomic data.
  • Collaborations to Improve Testing Access: Increased collaboration between healthcare providers, diagnostic companies, and government agencies is improving the accessibility of molecular testing in both developed and developing countries. These partnerships are focusing on making molecular testing technologies affordable and available to a wider patient population.
  • Integration of AI in Data Analysis for Molecular Testing: Artificial intelligence is being integrated into molecular testing platforms to analyze complex genetic data more efficiently. By improving the speed and accuracy of data interpretation, AI is helping clinicians make more informed decisions about treatment plans and disease monitoring.

These key developments are having a profound impact on the global onco-hematology molecular testing market. From FDA approvals and the growth of liquid biopsy to NGS advancements and AI integration, these innovations are improving diagnostic capabilities, enabling more personalized treatment, and expanding the reach of molecular testing. Together, they signal a future of more precise and accessible onco-hematology care.

Strategic Growth Opportunities in the Onco-Hematology Molecular Testing Market

The global onco-hematology molecular testing market is filled with growth opportunities in various applications. These opportunities reflect the continued demand for advanced diagnostic tools and treatments tailored to hematologic malignancies.

  • NGS for Precision Diagnosis: Next-generation sequencing (NGS) is becoming a critical tool for diagnosing hematologic cancers. By providing comprehensive insights into genetic mutations, NGS enables more precise diagnoses, better monitoring of disease progression, and personalized treatment plans, offering significant growth potential in both developed and emerging markets.
  • Liquid Biopsy for Non-Invasive Testing: The adoption of liquid biopsy technology is a key growth opportunity in onco-hematology testing. Liquid biopsy is gaining acceptance as a non-invasive, accurate method for detecting genetic mutations and monitoring treatment responses, making it a valuable tool in hematologic cancer care.
  • AI-Driven Diagnostic Tools: The integration of artificial intelligence (AI) into molecular testing platforms presents a growth opportunity by enhancing diagnostic accuracy and speed. AI algorithms can analyze vast amounts of genetic data more effectively, leading to earlier detection of hematologic malignancies and better-informed treatment decisions.
  • Expansion of Testing Access: There is a significant growth opportunity in expanding access to molecular testing in underserved regions. Public-private partnerships, alongside government support, can help make these advanced diagnostic tools affordable and accessible in developing countries, improving early detection and treatment outcomes in blood cancer care.
  • Targeted Therapies Based on Molecular Profiling: Molecular testing is crucial for identifying biomarkers that guide targeted therapies. The ability to offer personalized treatment for hematologic cancers such as leukemia and lymphoma creates a growth opportunity for molecular testing companies, especially those focused on developing and integrating new therapies.

The strategic growth opportunities in the onco-hematology molecular testing market highlight the industry's potential to improve diagnostic accuracy, patient outcomes, and treatment options. From NGS and liquid biopsy advancements to AI integration and targeted therapies, these opportunities will drive significant market growth and better patient care in the years to come.

Onco-Hematology Molecular Testing Market Driver and Challenges

The global onco-hematology molecular testing market is influenced by several drivers and challenges, shaping its growth trajectory and adoption of advanced diagnostic technologies.

The factors responsible for driving the onco-hematology molecular testing market include:

1. Technological Advancements in Diagnostics: The development of next-generation sequencing (NGS), liquid biopsies, and AI has revolutionized molecular testing. These technologies allow for more accurate, comprehensive, and less invasive testing methods, driving market growth by improving diagnosis and personalized treatment for hematologic cancers.

2. Rising Demand for Personalized Medicine: There is a growing demand for personalized medicine in oncology and hematology, with molecular testing playing a critical role in identifying genetic mutations and tailoring treatments. This demand drives the adoption of molecular diagnostics, as patients and healthcare providers seek more effective and targeted treatment options.

3. Government Support for Healthcare Innovations: Governments around the world are investing in healthcare innovations, including molecular diagnostics. Regulatory frameworks, such as those in the U.S. and China, promote the approval and adoption of advanced molecular testing technologies, providing a favorable environment for market growth.

4. Increasing Awareness of Hematologic Cancer: As awareness of hematologic cancers like leukemia and lymphoma increases, more patients are seeking early diagnostic tests. This awareness is driving the demand for molecular testing, particularly in regions where healthcare infrastructure is improving.

5. Growing Healthcare Expenditure: Higher healthcare spending globally, especially in emerging markets, is making advanced diagnostic tools more accessible. As healthcare budgets increase, more funds are allocated to cancer research and diagnostics, boosting the molecular testing market.

Challenges in the onco-hematology molecular testing market are:

1. High Cost of Molecular Testing: One of the major challenges is the high cost of advanced molecular testing technologies, which can limit accessibility for patients, particularly in low- and middle-income countries. Despite advances in technology, affordability remains a significant barrier.

2. Regulatory and Reimbursement Issues: Regulatory hurdles and lack of consistent reimbursement policies in different countries can slow the adoption of molecular testing. Variations in regulatory approval timelines and reimbursement criteria hinder the widespread use of new diagnostic tools.

3. Limited Healthcare Infrastructure in Developing Regions: Although demand is rising in emerging markets, limited healthcare infrastructure and a lack of trained professionals pose challenges to the adoption of advanced molecular testing technologies in these regions. Overcoming these barriers is key to global market growth.

The drivers of technological innovation, government support, and increasing demand for personalized care are helping shape the growth of the onco-hematology molecular testing market. However, challenges related to cost, regulatory issues, and healthcare infrastructure limitations must be addressed to fully realize the potential of these innovations. Addressing these challenges will be essential for expanding access to cutting-edge diagnostic tools worldwide.

List of Onco-Hematology Molecular Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies onco-hematology molecular testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the onco-hematology molecular testing companies profiled in this report include-

  • Asuragen
  • Bio-Rad Laboratories
  • Illumina
  • QIAGEN
  • Cepheid

Onco-Hematology Molecular Testing Market by Segment

The study includes a forecast for the global onco-hematology molecular testing market by type, application, and region.

Onco-Hematology Molecular Testing Market by Type [Value from 2019 to 2031]:

  • qPCR
  • dPCR
  • Next-Generation Sequencing
  • Others

Onco-Hematology Molecular Testing Market by Application [Value from 2019 to 2031]:

  • National Reference Lab / Specialty Lab
  • University Hospital
  • Community Hospital

Onco-Hematology Molecular Testing Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Onco-Hematology Molecular Testing Market

The global onco-hematology molecular testing market is evolving rapidly due to innovations in technology, growing healthcare demands, and improvements in diagnostic techniques. Countries like the United States, China, Germany, India, and Japan are key players, contributing significantly to advancements in cancer and blood disorder testing. This market's developments reflect efforts to enhance early detection, personalized treatment options, and patient outcomes across diverse global healthcare landscapes.

  • United States: The U.S. is at the forefront of onco-hematology molecular testing, driven by significant investments in precision medicine. The country is witnessing increased adoption of next-generation sequencing (NGS) and liquid biopsy technologies. The FDA's approval of several molecular diagnostic tools for hematologic cancers has catalyzed the growth of this market. Moreover, collaboration between biotech companies and healthcare providers is accelerating the development of personalized treatment strategies for patients with leukemia, lymphoma, and other blood cancers.
  • China: China's onco-hematology molecular testing market is experiencing rapid growth due to increasing healthcare access and technological advancements. The government's emphasis on enhancing its healthcare infrastructure and funding cancer research is contributing to the adoption of molecular diagnostics. Chinese companies are also focusing on the development of affordable testing solutions, while collaborations with global players are helping to introduce cutting-edge technologies like NGS and gene editing tools to diagnose hematological malignancies more effectively.
  • Germany: Germany is a leader in Europe for onco-hematology molecular testing, supported by a strong healthcare system and robust R&D efforts. With a high level of adoption of advanced technologies like NGS and PCR-based tests, Germany is making strides in the molecular profiling of hematologic cancers. Moreover, German healthcare institutions are prioritizing the development of minimally invasive diagnostic methods, such as liquid biopsies, to detect genetic mutations and alterations in blood disorders early on.
  • India: India's onco-hematology molecular testing market is expanding as the healthcare sector modernizes. Key drivers include improved healthcare access, greater awareness of cancer and blood disorders, and an increase in affordable diagnostic options. India is also experiencing a rise in public and private collaborations focused on introducing molecular diagnostic tools for hematologic cancers. With the growing burden of cancer in the country, advancements in testing technology and genetic profiling are enhancing personalized treatment approaches.
  • Japan: Japan's onco-hematology molecular testing market benefits from strong government support and advanced technology. Japan is known for its robust healthcare infrastructure, allowing for the swift integration of molecular diagnostics into clinical practice. The country's focus on precision medicine is driving innovations in diagnostic technologies, such as liquid biopsies and targeted sequencing, enabling the identification of genetic mutations and optimizing treatment strategies for hematologic malignancies like leukemia and lymphoma.

Features of the Global Onco-Hematology Molecular Testing Market

  • Market Size Estimates: Onco-hematology molecular testing market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Onco-hematology molecular testing market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Onco-hematology molecular testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the onco-hematology molecular testing market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the onco-hematology molecular testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the onco-hematology molecular testing market by type (qPCR, dPCR, next-generation sequencing, and others), application (national reference lab / specialty lab, university hospital, and community hospital), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Onco-Hematology Molecular Testing Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 qPCR: Trends and Forecast (2019-2031)
  • 4.4 dPCR: Trends and Forecast (2019-2031)
  • 4.5 Next-Generation Sequencing: Trends and Forecast (2019-2031)
  • 4.6 Others: Trends and Forecast (2019-2031)

5. Global Onco-Hematology Molecular Testing Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 National Reference Lab / Specialty Lab: Trends and Forecast (2019-2031)
  • 5.4 University Hospital: Trends and Forecast (2019-2031)
  • 5.5 Community Hospital: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Onco-Hematology Molecular Testing Market by Region

7. North American Onco-Hematology Molecular Testing Market

  • 7.1 Overview
  • 7.2 North American Onco-Hematology Molecular Testing Market by type
  • 7.3 North American Onco-Hematology Molecular Testing Market by application
  • 7.4 United States Onco-Hematology Molecular Testing Market
  • 7.5 Mexican Onco-Hematology Molecular Testing Market
  • 7.6 Canadian Onco-Hematology Molecular Testing Market

8. European Onco-Hematology Molecular Testing Market

  • 8.1 Overview
  • 8.2 European Onco-Hematology Molecular Testing Market by type
  • 8.3 European Onco-Hematology Molecular Testing Market by application
  • 8.4 German Onco-Hematology Molecular Testing Market
  • 8.5 French Onco-Hematology Molecular Testing Market
  • 8.6 Spanish Onco-Hematology Molecular Testing Market
  • 8.7 Italian Onco-Hematology Molecular Testing Market
  • 8.8 United Kingdom Onco-Hematology Molecular Testing Market

9. APAC Onco-Hematology Molecular Testing Market

  • 9.1 Overview
  • 9.2 APAC Onco-Hematology Molecular Testing Market by type
  • 9.3 APAC Onco-Hematology Molecular Testing Market by application
  • 9.4 Japanese Onco-Hematology Molecular Testing Market
  • 9.5 Indian Onco-Hematology Molecular Testing Market
  • 9.6 Chinese Onco-Hematology Molecular Testing Market
  • 9.7 South Korean Onco-Hematology Molecular Testing Market
  • 9.8 Indonesian Onco-Hematology Molecular Testing Market

10. ROW Onco-Hematology Molecular Testing Market

  • 10.1 Overview
  • 10.2 ROW Onco-Hematology Molecular Testing Market by type
  • 10.3 ROW Onco-Hematology Molecular Testing Market by application
  • 10.4 Middle Eastern Onco-Hematology Molecular Testing Market
  • 10.5 South American Onco-Hematology Molecular Testing Market
  • 10.6 African Onco-Hematology Molecular Testing Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Onco-Hematology Molecular Testing Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Asuragen
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Bio-Rad Laboratories
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Illumina
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 QIAGEN
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Cepheid
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Onco-Hematology Molecular Testing Market
  • Figure 2.1: Usage of Onco-Hematology Molecular Testing Market
  • Figure 2.2: Classification of the Global Onco-Hematology Molecular Testing Market
  • Figure 2.3: Supply Chain of the Global Onco-Hematology Molecular Testing Market
  • Figure 3.1: Driver and Challenges of the Onco-Hematology Molecular Testing Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Onco-Hematology Molecular Testing Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Onco-Hematology Molecular Testing Market ($B) by Type
  • Figure 4.3: Forecast for the Global Onco-Hematology Molecular Testing Market ($B) by Type
  • Figure 4.4: Trends and Forecast for qPCR in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 4.5: Trends and Forecast for dPCR in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Next-Generation Sequencing in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Others in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 5.1: Global Onco-Hematology Molecular Testing Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Onco-Hematology Molecular Testing Market ($B) by Application
  • Figure 5.3: Forecast for the Global Onco-Hematology Molecular Testing Market ($B) by Application
  • Figure 5.4: Trends and Forecast for National Reference Lab / Specialty Lab in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 5.5: Trends and Forecast for University Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Community Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 6.1: Trends of the Global Onco-Hematology Molecular Testing Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Onco-Hematology Molecular Testing Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 7.4: North American Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 7.6: Forecast for the North American Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.1: European Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 8.4: European Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 8.6: Forecast for the European Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.1: APAC Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 9.4: APAC Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 9.6: Forecast for the APAC Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 10.1: ROW Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 10.4: ROW Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 10.6: Forecast for the ROW Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Onco-Hematology Molecular Testing Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Onco-Hematology Molecular Testing Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Onco-Hematology Molecular Testing Market by Type
  • Figure 12.2: Growth Opportunities for the Global Onco-Hematology Molecular Testing Market by Application
  • Figure 12.3: Growth Opportunities for the Global Onco-Hematology Molecular Testing Market by Region
  • Figure 12.4: Emerging Trends in the Global Onco-Hematology Molecular Testing Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Onco-Hematology Molecular Testing Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Onco-Hematology Molecular Testing Market by Region
  • Table 1.3: Global Onco-Hematology Molecular Testing Market Parameters and Attributes
  • Table 3.1: Trends of the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 3.2: Forecast for the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Onco-Hematology Molecular Testing Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.4: Trends of qPCR in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.5: Forecast for qPCR in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.6: Trends of dPCR in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.7: Forecast for dPCR in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.8: Trends of Next-Generation Sequencing in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.9: Forecast for Next-Generation Sequencing in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.10: Trends of Others in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.11: Forecast for Others in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Onco-Hematology Molecular Testing Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.4: Trends of National Reference Lab / Specialty Lab in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.5: Forecast for National Reference Lab / Specialty Lab in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.6: Trends of University Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.7: Forecast for University Hospital in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.8: Trends of Community Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.9: Forecast for Community Hospital in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.1: Trends of the North American Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 7.2: Forecast for the North American Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various application in the North American Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various application in the North American Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.1: Trends of the European Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 8.2: Forecast for the European Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various application in the European Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various application in the European Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.1: Trends of the APAC Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 9.2: Forecast for the APAC Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various application in the APAC Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various application in the APAC Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 10.1: Trends of the ROW Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 10.2: Forecast for the ROW Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various application in the ROW Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various application in the ROW Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 11.1: Product Mapping of Onco-Hematology Molecular Testing Suppliers Based on Segments
  • Table 11.2: Operational Integration of Onco-Hematology Molecular Testing Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Onco-Hematology Molecular Testing Revenue
  • Table 12.1: New Product Launches by Major Onco-Hematology Molecular Testing Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Onco-Hematology Molecular Testing Market